Progressive External Ophthalmoplegia

Eye Deceases

(H49.4) Progressive External Ophthalmoplegia

Progressive External Ophthalmoplegia Introduction

 Once a patient is hit with Progressive External Opthalmoplegia, all ocular motility is lost. Largely, the adult population fall prey to this disease. Double vision is a common symptom among patients who suffer from Opthalmoplegia. In usual terms, Progressive external Opthalmoplegia is known as PEP.

ICD-10 H49.4
ICD-9 378.72
OMIM 157640
DiseasesDB 29124
eMedicine oph / 510
MeSH D017246

Progressive External Ophthalmoplegia Symptoms

  • Primarily, it occurs due to the paralysis or weakness of one or more of the muscles that control the movement of eye.
  • Secondly, this disease can result in hearing impairment.
  • Thirdly, PEP poses the potential danger of causing retinopathy, cerebellar disorders, and peripheral neuropathy.
  • Fourthly, Progressive External Opthalmoplegia can lead to diabetic, thyroid, pituitary or pancreas-related problems.  Further, it can give rise to kidney failure and heart disorders.
  • The eyelids of PEP-affected patients also tend to become thinner.

Causes of Progressive External Ophthalmoplegia

Opthalmoplegia is caused due to disintegration of muscles.  When a person is suffering from Opthalmoplegia, the patient always has a tired look on his face.

Occasionally, Progressive external Opthalmoplegia shows the symptoms of specific neurologic syndromes, which contain familial forms of spastic paraplegia, spino-cerebellar disorders, or sensorimotor peripheral neuropathy. Symptoms of the disease appear as early as at the age of 15.

Types of Progressive External Ophthalmoplegia

Progressive external Opthalmoplegia is classified as three different categories such as:

     A) Progressive External Opthalmoplegia A : Under this category, the disease infects people who are in the age  range of 25-35 .
     B) Progressive External Opthalmoplegia B: People of age range of 16-25 fall susceptible to the disease.
     C) Progressive External Opthalmoplegia C : This is more hereditary in nature  as people of  20-30 years of age are prone to the Progressive external Opthalmoplegia C.

Progressive External Ophthalmoplegia Treatment

There is no viable treatment which can treat the muscle weakness of Progressive External Opthalmoplegia.

Though Coenzyme Q (ubiquinone), akin to Vitamin K, is widely used to treat Progressive external Opthalmoplegia, the degree of success fluctuates.